- €1.31bn
- €1.35bn
- €796.97m
- 44
- 30
- 39
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.38 | ||
| Price to Tang. Book | 2.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.09% | ||
| Return on Equity | -18.92% | ||
| Operating Margin | -17.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 500.92 | 618.03 | 751.45 | 781.43 | 796.97 | 876.08 | 972.08 | 12.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -82.21 | +2399.82 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Directors
- Wolfgang Plischke CSU (69)
- Werner Lanthaler CEO (52)
- Iris Loewfriedrich VSU (60)
- Enno Spillner CFO (51)
- Craig Johnstone COO (51)
- Cord Dohrmann CSO (57)
- Mario Polywka IND (57)
- Elaine Sullivan IND (60)
- Kasim Kutay SUB (55)
- Roland Sackers SUB (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 29th, 2019
- Public Since
- October 11th, 1999
- No. of Employees
- 4,827
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 177,513,609
- Address
- Essener Bogen 7, HAMBURG, 22419
- Web
- https://www.evotec.com/
- Phone
- +49 40560810
- Contact
- Volker Braun
- Auditors
- BDO AG Wirtschaftsprufungsgesellschaft
Latest News for EVT
Upcoming Events for EVT
Evotec SE Swiss Biotech Day 2025
Q1 2025 Evotec SE Earnings Release
Q1 2025 Evotec SE Earnings Call
Evotec SE Annual Shareholders Meeting
Evotec SE Annual Shareholders Meeting
Half Year 2025 Evotec SE Earnings Release
Half Year 2025 Evotec SE Earnings Call
Similar to EVT
FAQ
As of Today at 20:32 UTC, shares in Evotec SE are trading at €7.38. This share price information is delayed by 15 minutes.
Shares in Evotec SE last closed at €7.38 and the price had moved by -19.41% over the past 365 days. In terms of relative price strength the Evotec SE share price has underperformed the FTSE Global All Cap Index by -21.43% over the past year.
The overall consensus recommendation for Evotec SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEvotec SE does not currently pay a dividend.
Evotec SE does not currently pay a dividend.
Evotec SE does not currently pay a dividend.
To buy shares in Evotec SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €7.38, shares in Evotec SE had a market capitalisation of €1.31bn.
Here are the trading details for Evotec SE:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: EVT
Based on an overall assessment of its quality, value and momentum Evotec SE is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Evotec SE is €12.70. That is 72.04% above the last closing price of €7.38.
Analysts covering Evotec SE currently have a consensus Earnings Per Share (EPS) forecast of -€0.38 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evotec SE. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +13.42%.
As of the last closing price of €7.38, shares in Evotec SE were trading +0.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Evotec SE PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €7.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Evotec SE's management team is headed by:
- Wolfgang Plischke - CSU
- Werner Lanthaler - CEO
- Iris Loewfriedrich - VSU
- Enno Spillner - CFO
- Craig Johnstone - COO
- Cord Dohrmann - CSO
- Mario Polywka - IND
- Elaine Sullivan - IND
- Kasim Kutay - SUB
- Roland Sackers - SUB